Dr. Jose Sandoval-Sus reviewed Hodgkin lymphoma advances, noting 80% cure rates and a shift to reduce toxicity. PET scans may be avoidable in early-stage cases. Trials like ECHELON-1, SWOG S1826, and HD21 support brentuximab and nivolumab combos. Future care focuses on genetics and MRD-guided strategies.